NASDAQ:ZNTL Stock Quote
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of cancer
The company's expertise lies in its ability to identify and target specific molecular pathways that drive cancer growth and progression. Zentalis is dedicated to advancing a pipeline of small molecules designed to address high unmet medical needs in oncology. Through a combination of scientific rigor and a commitment to patient care, the company aims to deliver effective treatment options that can improve outcomes for individuals battling cancer.
Frequently Asked Questions
Does Zentalis Pharmaceuticals engage in collaborations?
Yes, Zentalis Pharmaceuticals seeks collaborations with other biotech companies, academic institutions, and research organizations to enhance their drug development process, share knowledge, and potentially co-develop new oncology therapies.
Has Zentalis Pharmaceuticals received any FDA approvals?
As of the latest updates, Zentalis Pharmaceuticals has made progress in clinical trials but has not yet received FDA approvals for any of its drug candidates. They continue to advance their trials in hopes of obtaining regulatory approval in the future.
How does Zentalis approach drug development?
Zentalis Pharmaceuticals adopts a science-driven approach to drug development, engaging in rigorous preclinical and clinical research. They utilize innovative techniques such as medicinal chemistry and mechanism-based drug design to identify promising therapeutic candidates.
How does Zentalis engage with investors?
Zentalis Pharmaceuticals engages with investors through regular financial updates, press releases, conference calls, and participation in investment conferences. They aim to keep stakeholders informed about company progress, clinical trial developments, and financial health.
How does Zentalis support cancer research initiatives?
Zentalis Pharmaceuticals supports cancer research initiatives by investing in scientific research, participating in industry consortia, and collaborating with academic institutions to further understand cancer biology and discover new therapeutic targets.
What are some of Zentalis' most notable drug candidates?
Some of Zentalis' most notable drug candidates include ZN-c5, a treatment for solid tumors and hematological malignancies, and ZN-d5, which targets specific oncogenic pathways in cancer cells. The pipeline reflects a commitment to innovation in the oncology space.
What are the company's long-term goals?
Zentalis Pharmaceuticals' long-term goals include advancing its pipeline of oncology drug candidates through clinical trials, ultimately achieving FDA approval and successful commercialization, as well as expanding its research portfolio to include new cancer targets and therapies.
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is a biotechnology company focused on the development of innovative cancer therapies. The company specializes in designing and commercializing small-molecule therapeutics targeting various cancer indications, with the aim of improving patient outcomes through novel treatment approaches.
What is the financial outlook for Zentalis Pharmaceuticals?
The financial outlook for Zentalis Pharmaceuticals primarily depends on the successful development and commercialization of its drug candidates, ongoing clinical trial results, and market conditions. As a publicly traded company, its performance is closely monitored by investors and analysts.
What is the mission of Zentalis Pharmaceuticals?
The mission of Zentalis Pharmaceuticals is to improve the lives of cancer patients through the development of safe and effective therapeutic options. The company aims to harness cutting-edge research and technology in oncology to develop novel therapies.
What is Zentalis' clinical trial strategy?
Zentalis Pharmaceuticals employs a strategic clinical trial approach that includes phased trials to rigorously assess the safety and efficacy of their investigational therapies. They aim to design trials that provide actionable insights to optimize treatment protocols.
What recent milestones has Zentalis achieved?
Recent milestones for Zentalis Pharmaceuticals have included advancements in their clinical trial programs as well as the presentation of trial data at significant oncology conferences. These milestones help to illustrate the progress of their drug development initiatives.
What sets Zentalis apart from other oncology companies?
Zentalis Pharmaceuticals differentiates itself through its focus on small-molecule therapeutics and its commitment to developing drugs that target specific pathways in cancer biology. This precision approach aims to provide more effective treatment options for patients.
What stock exchange is Zentalis Pharmaceuticals listed on?
Zentalis Pharmaceuticals is listed on the Nasdaq stock exchange under the ticker symbol 'ZNTL', allowing investors to trade shares of the company's common stock.
What types of cancer therapies does Zentalis work on?
Zentalis Pharmaceuticals focuses on developing targeted therapies for a range of hematological and solid tumor cancers, utilizing small-molecule drugs that aim to interfere with cancer cell growth and proliferation.
When was Zentalis Pharmaceuticals founded?
Zentalis Pharmaceuticals was founded in 2014, with the mission of providing effective cancer treatments by leveraging scientific expertise and innovative drug development strategies.
Where is Zentalis Pharmaceuticals headquartered?
Zentalis Pharmaceuticals is headquartered in New York City, New York, which serves as a hub for its operations, research, and development efforts in the competitive biopharmaceutical industry.
Who are the key executives at Zentalis Pharmaceuticals?
The leadership team at Zentalis Pharmaceuticals includes experienced professionals from the biopharmaceutical industry, with backgrounds in research, clinical development, and commercialization of therapeutic products. Key executives typically include a CEO, CMO, CFO, and other vital roles.
What is the current price of Zentalis Pharmaceuticals, Inc. - common stock?
The current price of Zentalis Pharmaceuticals, Inc. - common stock is 1.385
When was Zentalis Pharmaceuticals, Inc. - common stock last traded?
The last trade of Zentalis Pharmaceuticals, Inc. - common stock was at 2:24 pm EDT on April 2nd, 2025
What is the market capitalization of Zentalis Pharmaceuticals, Inc. - common stock?
The market capitalization of Zentalis Pharmaceuticals, Inc. - common stock is 62.40M
How many shares of Zentalis Pharmaceuticals, Inc. - common stock are outstanding?
Zentalis Pharmaceuticals, Inc. - common stock has 45.05M shares outstanding.